Everist Genomics has launched four companion diagnostics intended to improve early diagnosis, management, and treatment of patients with colorectal cancer.
The tests, which will be available in the US at the end of March, include:
• OncoDefender-MMR, used for prognosis for colorectal cancer patients at all stages of the disease;
• OncoDefender-CRC, designed to identify early-stage colorectal cancer patients likely to benefit from adjuvant chemotherapy;
• OncoSelector, intended for patients who have tested positive with OncoDefender-CRC and used to help physicians determine which type of chemotherapy a colorectal cancer patient is likely to respond best to — 5-FU or irinotecan; and
• OncoDefender-Lynch syndrome, which identifies patients with Lynch syndrome, an inherited disorder that is associated with a high risk of developing colon cancer.
All tests are performed at the company's CLIA-certified laboratory in Ann Arbor, Mich. Everist said that OncoDefender MMR, OncoDefender-Lynch syndrome, and OncoSelector are reimbursable through private insurance and Medicare, subject to individual plan benefits.